FDA panelists expressed frequent puzzlement in the face of a deluge of data on metal-on-metal hip devices during a meeting last month, leaving some questions unanswered on what FDA’s next steps should be for the controversial products.
Significant discussion at the June 27-28 meeting of the agency’s Orthopaedic and Rehabilitation Devices Panel centered on the need for...